iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
10.02
-0.01 (-0.10%)
At close: May 30, 2025, 4:00 PM
10.05
+0.03 (0.30%)
After-hours: May 30, 2025, 7:45 PM EDT
iTeos Therapeutics Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for iTeos Therapeutics stock ranges from a low of $8.00 to a high of $12. The average analyst price target of $10.6 forecasts a 5.79% increase in the stock price over the next year.
Price Target: $10.60 (+5.79%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for iTeos Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $13 → $12 | Buy → Hold | Downgrades | $13 → $12 | +19.76% | May 28, 2025 |
| Wedbush | Wedbush | Buy → Hold Downgrades $10 → $12 | Buy → Hold | Downgrades | $10 → $12 | +19.76% | May 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 14, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $16 → $12 | Buy | Maintains | $16 → $12 | +19.76% | May 14, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $16 → $13 | Buy | Maintains | $16 → $13 | +29.74% | May 14, 2025 |
Financial Forecast
Revenue This Year
7.55M
from 35.00M
Decreased by -78.43%
Revenue Next Year
9.94M
from 7.55M
Increased by 31.74%
EPS This Year
-3.53
from -3.32
EPS Next Year
-2.50
from -3.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 38.9M | 35.4M | n/a | ||
| Avg | 7.5M | 9.9M | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.0% | 369.4% | - | ||
| Avg | -78.4% | 31.7% | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.31 | -1.25 | -2.12 | ||
| Avg | -3.53 | -2.50 | -3.53 | ||
| Low | -4.79 | -4.11 | -4.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.